Ankylosing Spondylitis News Archive
Patients with psoriatic arthritis had greater entheseal insertion damage scores compared with patients with ankylosing spondylitis.
No clear evidence links the risk for hospitalized infection and the use of DMARDs or anti-TNF agents in patients with ankylosing spondylitis.
The risk for primary total knee arthroplasty is elevated in young and middle-aged adults with ankylosing spondylitis.
Assessment of Simultaneous Occurrence of Ankylosing Spondylitis and Diffuse Idiopathic Skeletal Hyperostosis
Researchers explored the co-occurrence of ankylosing spondylitis and diffuse idiopathic skeletal hyperostosis.
Effective suppression of inflammation with tumor necrosis factor inhibitor therapy decreases radiographic progression in early ankylosing spondylitis.
Researchers observed increased rates of both knee and hip arthroplasties in older patients with ankylosing spondylitis.
Reduced cardiorespiratory fitness may be associated with increased risk for CVD in ankylosing spondylitis.
Treatment with risankizumab was not effective in reducing the signs and symptoms of ankylosing spondylitis at 12 weeks.
Results from a phase 3 study show positive results for ixekizumab in patients with ankylosing spondylitis.
Data strengthen the indication for performing a thorough CVD risk assessment in patients with inflammatory disorders.
Fatigue had a significant and independent effect on work disability measures in rheumatoid arthritis and ankylosing spondylitis.
Axial Psoriatic Arthritis and Ankylosing Spondylitis: Comparing Clinical, Radiologic Characteristics
It is unclear whether ankylosing spondylitis and axial psoriatic arthritis are part of a spectrum of the same disease, or whether they are separate diseases with overlapping features.
Dose-related use of NSAIDs together with TNFi in patients with ankylosing spondylitis has a synergistic effect in slowing radiographic progression.
Investigators assessed the 12-week efficacy and safety of bimekizumab in patients with active ankylosing spondylitis.
Researchers used data from social media to identify concerns and perceptions regarding biologic therapies.
Researchers assessed achievement of minimally important changes in SPARCC scores in biologic-naive patients with ankylosing spondylitis treated with tofacitinib or placebo.
A number of factors that include age, the presence of enthesitis, and depressive symptoms may be associated with neuropathic pain in ankylosing spondylitis.
Researchers sought to provide information on pregnancy outcomes, including major congenital malformations and other maternal and fetal adverse outcomes, in women treated with certolizumab pegol.
Nonmandatory transitioning from originator etanercept to biosimilar etanercept SB4 using a specifically designed communication strategy showed a slightly lower persistence rate and smaller decreases in disease activity.
TNFi therapy yielded favorable results in patients with AS or PsA, with progressively better responses between 4 months and 3 years.
The FDA has approved a label update to include pharmacokinetic data showing low transfer of certolizumab pegol through placenta and minimal transfer to breast milk from mother to infant.
Investigators evaluated sex differences in the effectiveness of tumor necrosis factor inhibitors in patients with ankylosing spondylitis.
Decreases in spinal and sacroiliac joint inflammation on MRI were maintained through 204 weeks with certolizumab pegol treatment.
The risk for aortic regurgitation and cardiac rhythm abnormalities was evaluated in a nationwide cohort of patients with spondyloarthritis.
Spinal fracture-free survival among patients with AS was not significantly affected by the use of bDMARD therapy.
Investigators examined the long-term safety and efficacy of a subcutaneous maintenance dose of secukinumab 150 and 300 mg.
Male gender and the Charlson Comorbidity Index score contributed significantly to fracture risk in this population.
Research suggests that the best site to assess bone loss in patients with ankylosing spondylitis is the femoral neck.
Low-dose computed tomography detects more bone proliferation in patients with ankylosing spondylitis compared with conventional radiography.
Transitioning from an originator agent to its biosimilar has the potential to reduce healthcare costs without compromising outcomes.
The use of tumor necrosis factor inhibitors to modify structural changes in axial spondyloarthritis may prevent progression to spinal disease.
Although the effect of antirheumatic drugs on inflammatory arthritic conditions has not been fully elucidated, treatment with methotrexate and tumor necrosis factor inhibitors has been found to improve endothelial dysfunction in this population.
For patients with ankylosing spondylitis, secukinumab may reduce radiographic progression and remain effective in the long-term.
The risk for cerebrovascular accidents and myocardial infarctions was assessed in patients with ankylosing spondylitis.
The SSDM series of applications is cost-effective for patients of rheumatologists.
Investigators sought to determine the long-term safety of adalimumab use in patients with arthritis and other immune-related diseases.
Simponi Aria has been approved by the FDA for treating PsA or ankylosing spondylitis.
Predictors of subclinical accelerated atherosclerosis were examined in a recent study of patients with spondyloarthritis without overt cardiovascular disease.
The first lactation study of its kind evaluated whether a biologic drug is transferred into mature breast milk
Cyltezo subcutaneous injection has been approved by the FDA.
In patients with AS, those with a BMI in the overweight or obese range had a lower likelihood of clinical improvement with tumor necrosis factor inhibitor therapy.
A study analyzes whether underlying sacroiliac erosions may be present in patients with nonradiographic axial spondylarthritis who have normal radiographs.
In ankylosing spondylitis, syndesmophytes are a more useful imaging marker of spinal fusion.
Serum leptin and high molecular weight adiponectin have an inverse relationship with radiographic spinal progression in patients with ankylosing spondylitis.
Determining which patients are unlikely to respond to therapy early on may help reduce unnecessary treatment and contain costs.
Patients saw a reduction in PSQI scores, but no change in polysomnography parameters.
Patients with panuveitis more often had biopsy-confirmed sarcoidosis than those with other anatomical locations of uveitis (20% vs 4%).
At seven-year follow-up, visual acuity was better with systemic therapy than with intravitreous fluocinolone acetonide implants.
In children with active juvenile idiopathic arthritis, the treatment combination controls eye inflammation.
Jonathan Krant, MD, FACP, confronts the issues surrounding biosimilar substitution for biologic treatments.
Researchers examined whether different TNF inhibitors were associated with different rates of anterior uveitis in patients with ankylosing spondylitis undergoing treatment with adalimumab, etanercept, or infliximab.
An observational cohort study of 4961 women with completed pregnancies and a recorded diagnosis of systemic inflammatory conditions.
Study evaluated breast milk samples from 17 lactating mothers diagnosed with rheumatoid arthritis, Crohn's disease, psoriatic arthritis, and axial spondyloarthritis/ankylosing spondylitis.
Connecticut considers rheumatoid arthritis and fibromyalgia for medical marijuana treatment, while Lyme disease-carrying deer ticks continue to invade Michigan. All this and more in this week's edition.
Research comes from meta-analysis of 25 population-based studies on 5 major forms of arthritis.
Only 1 in 6 patients who take NSAIDs for back pain achieved benefits from the therapy.
Collaborative document provides guidance on non-pharmacological and pharmacological management in patients with axial spondyloarthritis.
A retrospective cohort study found 1 in 5 non-steroidal anti-inflammatory drug (NSAID) adverse drug reactions is a hypersensitivity reaction.
Treatment Efficacy and Clinical Burden in Nonradiographic Axial Spondyloarthritis vs Ankylosing Spondylitis
New research compared treatment efficacy by drug class and clinical and humanistic burdens of nr-axSpA with those of AS.
The sBLAs included data from two Phase 3 studies that assessed the safety and efficacy of Simponi Aria 2mg/kg infusion every 8 weeks after two starter doses at Weeks 0 and 4 in adults with active psoriatic arthritis.
Data from a recent trail show patients with early axial spondyloarthritis (axSpA) had better outcomes when treated with IFX + NPX than with NPX monotherapy.
Study examines the relationship between bone marrow edema and neck pain in patients with rheumatoid arthritis and ankylosing spondylitis.
The reproducibility of radiographic SIJ classification and potential drivers of disagreement were examined in a SpA inception cohort.
Secukinumab treatment was associated with higher ASAS 20 response rates at weeks 16, 24, and 52 and ASAS 40 at weeks 24 and 52 compared with treatment with adalimumab.
In this meta-analysis, the researchers found that all TNF-α inhibitors were more effective at treating AS than placebo in direct comparisons, but no differences in efficacy or safety were found between individual TNF-α inhibitors in indirect comparisons.
The European League Against Rheumatism has released updated management guidelines to address cardiovascular disease risk assessment in patients with rheumatoid arthritis and other inflammatory arthritides.
A biosimilar to adalimumab (adalimumab-atto (Amjevita®, Amgen) has been approved by the US Food and Drug Administration (FDA) to treat moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and active ankylosing spondylitis.
Various studies have examined the link between ankylosing spondylitis (AS) and multiple malignances and autoimmune diseases.
Delayed diagnosis is associated with worse outcomes and poor treatment responses in patients with spondyloarthritis. Andrew Vreede, MD, University of Wisconsin School of Medicine and Public Health, presents a talk about how delays in diagnosing spondyloarthritis can affect access to therapy and long-term outcomes.
While colchicine may reduce risk of a second CV event in the general population, there is limited research on how colchicine may be used for control, treatment, or prevention.
Hip-joint lesions, number of affected peripheral arthritis joints, ASO, and CIC were found to be associated with higher rates of uveitis in AS.
Clinical Implications of the Recommended Approval of 2 Biosimilars: Interview With Allan Gibofsky MD
Rheumatology Advisor speaks with Allan Gibofsky, MD, a professor of medicine and public health at Weill Cornell Medical College and an attending rheumatologist at Hospital for Special Surgery in New York, about the recent panel recommendation for FDA approval of biosimilar versions of adalimumab and etanercept.
Patients with AS frequently present with radiographic vertebral fractures, a risk that is more pronounced with older patients, baseline low bone mineral density and those with advanced disease.
Male patients with ankylosing spondylitis had significant decreases in both total and appendicular lean mass, which were both related to higher disease activity and bone loss.
The manufacturer of an adlimumab biosimilar has filed a biologics license application (BLA) with the FDA
In the first study comparing simultaneous estimates of ankylosing spondylitis (AS) management by PCPs and rheumatologists, researchers found that only approximately one-third of patients with clinically diagnosed AS were being managed by specialists
The U.S. Food and Drug Administration has approved adalimumab (Humira®, Abbvie), a potent blocker of tumor necrosis factor alpha, for the treatment of non-infectious intermediate, posterior, and panuveitis
A biomarker of collagen turnover in spondyloarthropathies may aid in early diagnosis and treatment
Researchers assessed incidence rates of age and sex-adjusted cardiovascular disease in patients with ankylosing spondylitis and rheumatoid arthritis, comparing these rates to those of the general population.
Therapeutic anti-TNF antibodies, long thought to act primarily via blockade of proinflammatory soluble TNF, appear to also bind membrane-bound TNF supporting regulatory T-cell expansion suppressing further inflammation.
In a large cohort study, men 60 to 69 years of age with newly diagnosed AS were at a higher risk for CVD at 5 years follow-up compared to the general population.
Uveitis may occur in patients with ankylosing spondylitis, juvenile rheumatoid arthritis, Behcet's disease, and HLA B27-associated seronegative spondyloarthropathies. Prompt initiation of treatment may improve clinical outcomes, emphasizing the importance of collaboration between rheumatologists and ophthalmologists.
Fecal levels of calprotectin have been used as biomarkers of inflammatory bowel disease activity, and researchers speculated that its levels may be viable markers for bowel involvement in spondyloarthritis as well.
Cervical spine fracture was identified as the leading cause of in-hospital mortality in patients with ankylosing spondylitis.
The current research on adherence to interventions for arthritis has shown inconsistent impacts on disease outcomes.
Results were reported from an open-label, single-arm, multicenter extension study assessing the long-term efficacy and safety of multiple doses of the infliximab biosimilar CT-P13 in patients with ankylosing spondylitis.
Work disability can have economic consequences for patients with chronic diseases, but it can also impact self-esteem, emotional life, and autonomy of the persons experiencing the disease.
Researchers evaluated the possible role that non-conventional human leukocyte antigen-B27 free heavy chains may play in the pathogenesis of AS.
This Phase 2 trial of clazakizumab represented the first time an IL-6-targeted therapy has been evaluated in psoriatic arthritis.
Tapering of anti-TNF therapy can facilitate sustained remission or lower disease activity in most patients with axial spondyloarthritis while ameliorating both risk for adverse events and treatment costs.
This study attempted to quantify the effects of peer-led education on quality of life in patients with ankylosing spondylitis.
A recent study published in The Journal of Rheumatology found that patients with AS have an increased risk of developing certain depressive disorders following their diagnosis.
To examine a potential immunologic mechanism for sex differences in AS, researchers examined data from serum samples obtained from a cohort of females and males with AS and from sex- and age-matched controls.
The USPSTF concludes with moderate certainty a moderate net benefit in screening at-risk adults for latent tuberculosis infection (LTBI).
The development of advanced lesions in AS is thought to be influenced, in part, by vascular proliferation, with vascular endothelial growth factor (VEGF) playing a regulatory role in that process.
In this study, biologic DMARD therapy was not associated with an increased incidence of virus-associated cancers in female patients with inflammatory arthritis.
AA amyloidosis is a rare but significant complication of ankylosing spondylitis (AS) and may lead to proteinuria and renal dysfunction.
The growing use of expensive biologics has led public and private insurers in the United States to impose cost-sharing burdens that place these drugs out of reach for many patients. The FDA is anticipating a marked increase in the biosimilar market as more patents expire for brand-name biologics.
Women who received anti-TNF agents during pregnancy did not have a significantly higher risk of having children with birth defects.
Enteropathic spondyloarthritis (ESpA) encompasses a group of rheumatic disorders that share overlapping pathophysiology with other immune system disorders, particular those of the gut. Therefore, a multidisciplinary approach is important to recognizing the varied manifestations of ESpA in patients with IBD in order to achieve a prompt and accurate diagnosis leading to comprehensive care.
Rheumatology Advisor Articles
- Synovial Thickening on Ultrasonography May Predict Arthritis Development
- Lutikizumab May Not Improve Outcomes in Erosive Hand Osteoarthritis
- Tender Joint Count May Not Reflect Inflammation Activity in Rheumatoid Arthritis
- Urine Immunoassay Identifies Novel Lupus Nephritis Biomarkers
- Smoking Linked to Increased Disease Activity in Rheumatoid Arthritis
- Using Telemedicine in Rheumatology: Outcomes, Costs, and Patient Satisfaction
- New Appointment Algorithm Helps Clinicians Manage Time Better
- Urine Immunoassay Identifies Novel Lupus Nephritis Biomarkers
- Ultrasound: A Sensitive Imaging Tool for Evaluating Suspected CPPD in Hip Joints
- Managing Bisphosphonate Drug Holidays in Patients With Osteoporosis
- No Clinically Meaningful Safety Differences Between Sarilumab, Tocilizumab in RA
- Biologic Therapies in JIA: International Registry Data Combined
- Risk Factors Associated With Chronic Opioid Use in Musculoskeletal Pain
- DHS, HHS Proposal Set to Upend Health Care for Non-Citizen Children
- Protecting Your Practice From Data Breaches: An Expert Interview